Yohei Yamamoto RT, Presenter: Nothing to Disclose

Tomonori Isobe PhD, Abstract Co-Author: Nothing to Disclose

Izumi Anno MD, PhD, Abstract Co-Author: Nothing to Disclose

Yasushi Sibata MD, PhD, Abstract Co-Author: Nothing to Disclose

Manabu Minami MD, PhD, Abstract Co-Author: Nothing to Disclose

Akira Matsumura MD, Abstract Co-Author: Nothing to Disclose

Proton MRS is the examination which detects slight signal. Because of that, various factors effects proton MRS. The recent proton MRS report has suggested that Gd-contrast agent causes artifacts in spectra. But, Other medicines are not reported. This study was aimed to examine the effects of medicines in proton MRS.

This study measuring medicines that is infusion solution (Soldem3A), Acetazolamide (Diamox), non-ionic iodine contrast agents and ionic iodine contrast agent. Non-ionic iodine contrast agents is Iopamidol (Iopamiron), Iohexiol (Omnipaque), Ioversol (Optiray) and Iomeprol (Iomeron). Ionic iodine contrast agent is Ioxaglic acid, Ioxaglate (Hexabrix). It makes a dilution of medicines by ten times in distillated water. Those was put in glass chamber (diameter：60 mm, hight：150 mm). And, that chamber was put in glass chamber (diameter：150 mm, hight：250 mm) as big as human body head. The inside of phantom was filled with saline solution. Proton MRS was performed using a clinical 1.5-T super-conducting MR system (Philips). Data were acquired by using a point resolved spectroscopy (PRESS) sequence with TR 2000 ms, TE 136 and 272 ms. The volume of interest was a single-voxel of 20 x 20 x 20 mm. The chemical shift of phantom was calibrated by setting the water signal to 4.7 ppm.

We have identified several characteristic resonances in proton MRS of phantom. The peak was resonating at 1.15 and 1.24 ppm in infusion solution (Soldem 3A), 2.17 ppm in Acetazolamide (Diamox), 1.42 ppm in Iopamidol (Iopamiron), 1.83 and 2.31 ppm in Iohexiol (Omnipaque), 3.75 ppm in Ioversol (Optiray), 3.08 and 3.63 ppm in Iomeprol (Iomeron), 1.77, 2.23, 2.65 and 3.02 ppm in Ioxaglate (Hexabrix).

We were able to catch the peak of the medicine phantom. The peak was related -CH3, -CH2, and -CH that medicine possessed. And, the chemical shift of the peak overlap the peak of brain metabolites.Therefore, our results indicate that you acquire the spectrum after administration of a medicine, it is necessary to consider the effects that those medicines give the spectrum.

Proton MRS is the examination which detects the peak of brain metabollites..

Yamamoto, Y, Isobe, T, Anno, I, Sibata, Y, Minami, M, Matsumura, A, The Effects of Medicine In Proton MRS: Phantom Study.  Radiological Society of North America 2007 Scientific Assembly and Annual Meeting, November 25 - November 30, 2007 ,Chicago IL. http://archive.rsna.org/2007/5016508.html